Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M milestone

Plus, news about Candel, Inovio and RemeGene: Eisai licenses Newron Pharmaceuticals’ evenamide: Eisai’s subsidiary EA Pharma will pay up to €117 million ($123 million) in upfront and milestone fees for rights to the treatment ...